AEON Stock Overview
A clinical stage biopharmaceutical company, focuses on developing botulinum toxins. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
AEON Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.53 |
| 52 Week High | US$17.17 |
| 52 Week Low | US$0.52 |
| Beta | 0.40 |
| 11 Month Change | -47.51% |
| 3 Month Change | -43.22% |
| 1 Year Change | -89.69% |
| 33 Year Change | -94.56% |
| 5 Year Change | n/a |
| Change since IPO | -94.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| AEON | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -14.1% | 2.5% | 2.2% |
| 1Y | -89.7% | 16.1% | 31.6% |
Return vs Industry: AEON underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: AEON underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| AEON volatility | |
|---|---|
| AEON Average Weekly Movement | 14.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AEON's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AEON's weekly volatility has decreased from 22% to 15% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 5 | Marc Forth | www.aeonbiopharma.com |
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
AEON Biopharma, Inc. Fundamentals Summary
| AEON fundamental statistics | |
|---|---|
| Market cap | US$20.95m |
| Earnings (TTM) | -US$305.52m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs AEON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AEON income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$305.52m |
| Earnings | -US$305.52m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.73 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -47.6% |
How did AEON perform over the long term?
See historical performance and comparison